Melanoma
Conditions
Brief summary
This clinical trial tests the feasibility of patient reported outcomes monitoring with early, rapid immunotherapy toxicity subspecialty care to improve side effect management for patients with melanoma receiving an immune checkpoint inhibitor. Immune checkpoint inhibitors have improved outcomes for patients with advanced melanoma, but their use is frequently complicated by immune related adverse events (irAEs). IrAEs can affect any organ system, range in severity from mild to life threatening, and often require a pause or stopping of immunotherapy treatment. Early identification and management of irAEs may reduce progression to severe toxicity. Electronic patient self reporting of symptoms with ways to support early involvement of non oncology subspecialists may be a feasible way to improve side effect management for patients with melanoma receiving an immune checkpoint inhibitor.
Detailed description
PRIMARY OBJECTIVE: I. Determine the feasibility of an electronic patient reported outcome (ePRO)-based symptom monitoring and subspecialty care referral intervention for identifying and managing irAEs in patients with melanoma. SECONDARY OBJECTIVES: I. Evaluate intervention acceptability for key stakeholders, including patients, caregivers, oncologists, and subspecialists. II. Describe the preliminary efficacy of the intervention to improve management of irAEs. OUTLINE: Patients complete an ePRO assessment, where they rate the frequency and/or severity of symptoms that may indicate a moderate to severe irAE, weekly for 6 months. If a patient rates a symptom at a frequency or severity level of moderate or higher, a care provider is notified and determines if the symptoms warrant evaluation by a non-oncology subspecialist or can be managed by medical oncology. Patients receive a referral to an appropriate subspecialist, complete an evaluation of the suspected irAE, within 14 days of the referral, and receive standard of care treatment. Patients may optionally have their caregiver enroll to complete an intervention acceptability survey.
Interventions
OTHERElectronic Health Record Review
Ancillary studies
OTHERInternet-Based Intervention
Receive access to ePRO tool
BEHAVIORALPatient Navigation
Receive review of symptoms and referral if needed
OTHERSurvey Administration
Complete ePRO assessments
Sponsors
OHSU Knight Cancer Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* PATIENT: Age 18 years or older * PATIENT: Histologically confirmed diagnosis of melanoma * PATIENT: Plan to begin a standard of care (SOC) immune checkpoint inhibitor (ICI) for the treatment of melanoma per Food and Drug Administration (FDA) approval and/or National Comprehensive Cancer Network (NCCN) guidelines * PATIENT: Willing and able to provide informed consent * CAREGIVER: Age 18 years or older * CAREGIVER: Family member or primary caregiver of a study participant
Exclusion criteria
* PATIENT: Previously received ICI therapy * PATIENT: Life expectancy of \< 6 months at time of enrollment * PATIENT: Concurrently receiving a non-ICI systemic therapy * PATIENT: Concurrently receiving radiation, unless hypofractionated palliative radiation prescribed to alleviate poorly controlled symptoms (e.g., pain) * PATIENT: Needs to rely on a proxy to complete patient-reported outcome instruments * PATIENT: Unwilling or unable to complete surveys electronically * CAREGIVER: Needs to rely on a proxy to complete survey instrument(s) * CAREGIVER: Unwilling or unable to complete surveys electronically
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of eligible patients who consent to the study and begin the intervention (feasibility of study enrollment) | At enrollment | Will estimate the proportion of patients enrolled with 95% confidence intervals. |
| Proportion of patients evaluated by subspecialists in ≤ 14 days among participants who enrolled and developed a suspected immune related adverse events (irAE) (grade 2 or higher) (feasibility of intervention delivery) | From baseline to 6 months | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients who complete data collection at 6 months (retention) | At month 6 | Will estimate the proportion of patients retained in the study and adherent to electronic patient reported outcomes with 95% confidence intervals. |
| Proportion of weeks a Patient Reported Outcome-Common Terminology Criteria for Adverse Events questionnaire was completed out of the number of weeks since starting the intervention (ePRO adherence) | From baseline to 6 months | — |
| Proportion of participants rating the study as acceptable (acceptability) | At 6 months | Assessed via adapted from Basch et al's survey. Acceptability is defined as a mean summary score of 3 or higher. |
| Proportion of caregivers for enrolled participants rate the study as acceptable (acceptability) | At 6 months | Assessed via adapted from Basch et al's survey. Acceptability is defined as a mean summary score of 3 or higher. |
| Proportion of medical oncologists/subspecialists rate the study as acceptable (acceptability) | At end of the study, up to 3 years | Assessed via clinician experience measure. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORDeanne Tibbitts
OHSU Knight Cancer Institute
Outcome results
None listed